Associated Papers
Gene therapy targeting synaptopathy linked with Alzheimer's and Parkinson's disease.
Panda SP et al.
Neuroscience, 2026
Hemoglobin as a pseudoperoxidase and drug target for oxidative stress-related diseases.
Won W et al.
Signal Transduction and Targeted Therapy, 2025
40846833 (PubMed )
Supplement: 41392_2025_2366_MOESM1_ESM.docx
Role of lysosomes in physiological activities, diseases, and therapy.
Zhang Z et al.
Journal of Hematology & Oncology, 2021
Current Evidence for a Bidirectional Loop Between the Lysosome and Alpha-Synuclein Proteoforms.
Wildburger NC et al.
Frontiers in Cell and Developmental Biology, 2020
Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies.
Xilouri M et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2016
Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant.
Hoenen C et al.
Plos One, 2016
Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function.
Oaks AW et al.
Plos One, 2013
Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration.
Wales P et al.
Journal of Parkinson's Disease, 2013
On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.
Daniëls V et al.
Neuro-signals, 2011
Autosomal dominant Parkinson's disease and the route to new therapies.
Morris HR
Expert Review of Neurotherapeutics, 2007
Fe(II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay.
Martin FL et al.
Journal of Neurochemistry, 2003
Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
Dev KK et al.
Neuropharmacology, 2003
Select a paper to view details